Last reviewed · How we verify

Fluoxetine + Valsartan — Competitive Intelligence Brief

Fluoxetine + Valsartan (Fluoxetine + Valsartan) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SSRI + ARB combination. Area: Psychiatry / Cardiovascular.

marketed SSRI + ARB combination Serotonin transporter (SERT) and Angiotensin II type 1 receptor (AT1R) Psychiatry / Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Fluoxetine + Valsartan (Fluoxetine + Valsartan) — National Cheng-Kung University Hospital. This combination pairs a selective serotonin reuptake inhibitor with an angiotensin II receptor blocker to address both mood and blood pressure regulation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Fluoxetine + Valsartan TARGET Fluoxetine + Valsartan National Cheng-Kung University Hospital marketed SSRI + ARB combination Serotonin transporter (SERT) and Angiotensin II type 1 receptor (AT1R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SSRI + ARB combination class)

  1. National Cheng-Kung University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fluoxetine + Valsartan — Competitive Intelligence Brief. https://druglandscape.com/ci/fluoxetine-valsartan. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: